No. 307 Hospital of PLA, Beijing Established in 1957, the No. 307 Hospital of PLA is the Affiliated Hospital of Academy of Military Medical Sciences. Among the top tier hospitals in China, the hospital has 38 specialty groups with over 1,600 beds. Its clinical trial center is certified by the China CFDA for Phase I clinical studies and Phase II/III/IV clinical studies for cancer, hematology, anti-radiation, detoxification and anti-dependency drugs. Over the years, the clinical trial center has conducted clinical trials for over two hundred sponsors, including 8 of the top 10 global pharmaceutical companies.
MicroConstants China and the Phase I Unit of No. 307 Hospital began implementing ICH GCP quality systems in late 2008, including SOPs development/training, hands-on QA/GCP training, procedures/process development, GLP/GCP training at MicroConstants Beijing and San Diego facilities, QA audit and CAPA implementation, CTMS implementation, SIDCER/FERCAP accreditation of Ethic Committee, and project co-management for oversea pharmaceutical clients. Now, the Phase I Unit is qualified by several major pharmaceutical companies and leading CROs for PK and BE projects and awarded the “best clinical trial center serving G20 enterprises” by the Beijing City government. MicroConstants China QA personnel is actively involved in the quality assurance at the Phase I Unit and this collaboration is an example of how we work with our clinical center partners to implement ICH GCP quality systems, to ensure GCP compliance. Strategic Partner: ERT
No. 301 Hospital of PLA, Beijing. Established in 1958, the No. 301 Hospital of PLA (the General Hospital of PLA) is one of the most prestigious hospitals in China with 125 clinical, medical and technical departments and 4,000 beds. Its clinical trial center is certified by the China CFDA for Phase I clinical studies and Phase II/III/IV clinical studies for cardiology, oncology, hematology, neurology, endocrinology, immunology, respiratory, and urology drugs. Its clinics have over 3.8 million outpatient visits each year.
Peking University No.6 Hospital, Beijing. A leading Psychiatry specialty hospital in China with over 200 beds. It has conducted several NIH sponsored clinical research programs for psychological drugs in various patient populations. It specializes in conducting clinical trials for depression, Alzheimer’s disease, and autism.
The Shanghai Mental Health Center (SMHC), Shanghai. Formerly known as the Shanghai Psychiatric Hospital, SMHC was founded in 1958. Its predecessor, Mercy Hospital, was established in 1935. The center is involved in teaching, research, and mental health prevention planning for Shanghai and China. It is one of the WHO collaborating centers for research and training in mental health. With 1,878 beds and thousands of outpatients each day, it is the leading clinical trial center for Psychiatry drugs in China.
Shengyang General Hospital of PLA, Shenyang, Liaoning. Established in 1948, the Shengyang General Hospital of PLA is one of the largest hospitals in Northeast China with 1,200 beds and 44 specialty groups. Its clinical trial center is certified by the China CFDA for Phase I clinical studies and Phase II/III/IV clinical studies for cardiology, oncology, hematology, neurology, endocrinology, immunology, respiratory, pain management, ophthalmology and urology drugs.
Aerospace Central Hospital, Beijing. Established in 1958, the Aerospace Central Hospital (ASCH) is under the China Aerospace Group and is one of the largest civilian hospital in Southern Beijing with 550 beds and 38 specialty groups. Its clinical trial center is certified by China CFDA for Phase I clinical studies and Phase II/III/IV clinical studies for cardiology, respiratory, GI tract and neurology drugs. It is also the medical training hospital of Peking University.
Clinical Trials Centre (CTC) of The University of Hong Kong (HKU), Hong Kong. HKU CTC is a leading academic research organization in Asia dedicated to one-stop clinical research solutions. Established in 1998, CTC is committed to enhancing global healthcare by promoting the quality and efficiency of clinical research and testing of new chemical drugs, biologics, vaccines, traditional Chinese medicines, medical devices and diagnostic tools through ethical consideration, scientific expertise, quality assurance and education. It is CFDA GCP certified and its newly opened state of art Phase I Unit can carry out various early stage clinical studies according to ICH GCP guidelines.